Cargando…
Evaluation of omadacycline against intracellular Mycobacterium abscessus in an infection model in human macrophages
BACKGROUND: Omadacycline is an aminomethylcycline antibiotic in the tetracycline class that was approved by the US FDA in 2018 for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. It is available in both IV and oral formulations. Omadacy...
Autores principales: | Jahanbakhsh, S, Howland, J, Ndayishimiye Uwineza, M O, Thwaites, M T, Pillar, C M, Serio, A W, Anastasiou, D M, Hufnagel, D A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502775/ https://www.ncbi.nlm.nih.gov/pubmed/37720564 http://dx.doi.org/10.1093/jacamr/dlad104 |
Ejemplares similares
-
Omadacycline Potentiates Clarithromycin Activity Against Mycobacterium abscessus
por: Bich Hanh, Bui Thi, et al.
Publicado: (2021) -
Omadacycline for the Treatment of Mycobacterium abscessus Disease: A Case Series
por: Pearson, Jeffrey C, et al.
Publicado: (2020) -
Long-term Safety and Tolerability of Omadacycline for the Treatment of Mycobacterium abscessus Infections
por: Mingora, Christina M, et al.
Publicado: (2023) -
Omadacycline as a promising new agent for the treatment of infections with Mycobacterium abscessus
por: Bax, Hannelore I, et al.
Publicado: (2019) -
Preliminary, Real-world, Multicenter Experience With Omadacycline for Mycobacterium abscessus Infections
por: Morrisette, Taylor, et al.
Publicado: (2021)